HIVEP1 Inhibitors
Chemical inhibitors of HIVEP1 include a variety of compounds that function by disrupting signaling pathways which are crucial for the protein's activity. SB203580 and SB202190 are specific inhibitors of p38 MAP kinase, a key player in the MAPK signaling pathway, which is known to influence the activity of various transcription factors, including HIVEP1. By inhibiting p38 MAPK, these chemicals can reduce the transcriptional activity of HIVEP1 by preventing its activation, which is often dependent on phosphorylation events that are mediated by the MAPK pathway. Similarly, the MEK inhibitors PD98059, U0126, and SL327, operate within the same MAPK pathway, but at an upstream kinase level. These inhibitors effectively reduce the phosphorylation of ERK1/2, a downstream effector in the MAPK cascade, thus indirectly limiting the functional capacity of HIVEP1, as the protein's activity can be regulated through the MAPK-mediated signaling mechanisms.
Furthermore, chemicals like LY294002 and Wortmannin target the PI3K/AKT pathway, with LY294002 specifically inhibiting PI3K, leading to a reduction in AKT phosphorylation. AKT is a serine/threonine-specific protein kinase that plays a critical role in multiple cellular processes, including transcription. The inhibition of this pathway can indirectly reduce HIVEP1 transcriptional activity by altering the network of regulators that control its function. Rapamycin, another chemical in the list, inhibits mTOR, a component of the PI3K/AKT/mTOR pathway. The inhibition of mTOR by Rapamycin can result in decreased cellular responses that would otherwise enhance HIVEP1 activity, as the protein is sensitive to changes in growth factor signals that are transmitted through this pathway. Src family kinase inhibitors, PP2 and Dasatinib, also contribute to the indirect inhibition of HIVEP1 by targeting Src kinases that are involved in various signaling pathways that regulate transcription factors. By inhibiting these kinases, PP2 and Dasatinib can alter the signaling environment of HIVEP1, affecting its activity. Lastly, PD173074, by inhibiting the FGFR tyrosine kinase, can disrupt downstream signaling pathways that intersect with the regulatory pathways of HIVEP1, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. HIVEP1 is a DNA-binding protein that can be influenced by the p38 MAPK signaling pathway. By inhibiting p38 MAPK, SB203580 can reduce the transcriptional activity of HIVEP1 by preventing its phosphorylation and subsequent activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that works upstream of ERK1/2 in the MAPK pathway. As HIVEP1 activity can be regulated by MAPK pathway signaling, inhibiting MEK with PD98059 can lead to decreased ERK activation, and consequently, reduced HIVEP1 function due to impaired signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). It can indirectly inhibit HIVEP1 by blocking JNK signaling pathways that may modulate the activity of transcription factors and co-regulators associated with HIVEP1 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to a reduction in AKT phosphorylation. As AKT can modulate various transcription factors and co-regulators, this inhibition can indirectly reduce HIVEP1 transcriptional activity by altering its regulatory network. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. By inhibiting these kinases, U0126 can decrease ERK pathway signaling, thereby reducing the phosphorylation and activity of proteins that may regulate HIVEP1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Rapamycin can lead to reduced cellular responses to growth factors that would otherwise enhance HIVEP1 activity through this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which, like LY294002, can lead to decreased AKT activity. This reduction in PI3K/AKT signaling can result in diminished activation of downstream proteins that control HIVEP1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases can influence various signaling pathways, including those regulating transcription factors. Inhibition by PP2 can, therefore, indirectly affect HIVEP1 function by altering its signaling environment. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190 is an inhibitor of p38 MAP kinase similar to SB203580. It can indirectly inhibit HIVEP1 by preventing the activation of signaling cascades that modulate the activity of HIVEP1-related transcriptional regulation. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of MEK, which consequently decreases ERK signaling. By inhibiting MEK and thus reducing ERK activity, SL327 can indirectly affect HIVEP1 function by impacting its regulation through the MAPK pathway. | ||||||